Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Minimal Residual Disease

Minimal Residual Disease

7

Pipeline Programs↗

7

Active Trials↗

2

Companies Involved↗

Minimal Residual Disease is an early-stage landscape with 7 programs across 2 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

40/100

Attrition Rate

21/100

Pipeline

Programs by Phase

Preclinical2

Adjuvant PD-1 Inhibitors

Tongji Hospital

Toripalimab (JS001 ) Lenvatinib

Shanghai Junshi Bioscience Co., Ltd.

Phase 1

No programs

Phase 24

Tislelizumab

BeiGene

Fruquintinib

Takeda

Daravrd/daravcd

University of Alabama at Birmingham

Inotuzumab Ozogamicin

Wyeth-Lederle Vaccines

Phase 31

Isatuximab

Azienda U.S.L. 1 di Massa e Carrara

Approved

No programs

Analysis

Modality Breakdown

7programs

Small molecule457%

Monoclonal antibody229%

Antibody–drug conjugate114%

Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

14

clinical trials

Terminated3 · 21%

Active, not recruiting3 · 21%

Not yet recruiting3 · 21%

Unknown status2 · 14%

Completed2 · 14%

Recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT04991103·40 enrolled

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05456698·31 enrolled

MInimal Residual Disease Adapted Strategy

Active, not recruiting·IIntergroupe Francophone du Myelome·Phase 3·NCT04934475·791 enrolled

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07136077·15 enrolled

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Not yet recruiting·TTongji Hospital·N/A·NCT07350824·276 enrolled

Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

Not yet recruiting·GGuangdong Association of Clinical Trials·N/A·NCT06709274·342 enrolled

Minimal Residual Disease in Solid Malignancies

Not yet recruiting·EEuropean Institute of Oncology·N/A·NCT07268469·840 enrolled

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled

Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery

Completed·TThe Institute of Molecular and Translational Medicine, Czech Republic·Phase 4·NCT02314871·60 enrolled

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01258933·4 enrolled

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Terminated·UUniversity of Pennsylvania·Phase 2·NCT02935543·1 enrolled

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05601830·1 enrolled

Interferon α for the Therapy of Minimal Residual Disease

Unknown status·PPeking University People's Hospital·N/A·NCT02185261·81 enrolled

Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

Unknown status·—·N/A·NCT05837689·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)